MedTrace Logo

Effect of Atorvastatin on Fractional Flow Reserve in Coronary Artery Disease

NCT01946815 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 119

Last updated 2023-04-12

No results posted yet for this study

Summary

Natural course of intermediate coronary artery disease (CAD) is very important to predict the prognosis of the patient with such disease.

Several studies have well demonstrated the beneficial effect of lipid-lowering therapy on the progression of CAD with the modification of lipid profiles.

This effect can be also explained by intravascular ultrasound (IVUS) or optical coherence tomography. However, the effect of plaque modification on coronary physiology has been rarely evaluated.

This research is to evaluate the change of intermediate or nonculprit coronary lesion on lipid-lowering therapy via IVUS(optional) and FFR.

Conditions

Interventions

DRUG

Atorvastatin

Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.

Sponsors & Collaborators

  • Seoul National University Hospital

    collaborator OTHER

  • Ulsan University Hospital

    collaborator OTHER

  • Inje University Ilsan Paik Hospital

    collaborator OTHER

  • Keimyung University Dongsan Medical Center

    lead OTHER

Principal Investigators

  • Chang-Wook Nam, Postdoctoral · Keimyung University Dongsan Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2018-11-30
Completion
2018-11-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01946815 on ClinicalTrials.gov